As of 2026-03-24, the Intrinsic Value of Nirvana Life Sciences Inc (NIRV.CN) is -0.03 CAD. This NIRV.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.01 CAD, the upside of Nirvana Life Sciences Inc is -669.73%.
Based on its market price of 0.01 CAD and our intrinsic valuation, Nirvana Life Sciences Inc (NIRV.CN) is overvalued by 669.73%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.03 - -0.03 | -0.03 | -669.73% |
| DDM - Stable | 0.25 - 0.37 | 0.31 | 6075.6% |
| DDM - Multi | 0.25 - 0.26 | 0.26 | 5005.2% |
| Market Cap (mil) | 0.33 |
| Beta | -4.38 |
| Outstanding shares (mil) | 66.00 |
| Enterprise Value (mil) | 0.47 |
| Market risk premium | 5.10% |
| Cost of Equity | 2.50% |
| Cost of Debt | 5.00% |
| WACC | 2.77% |